loading page

A Review On: Current status of Liposome In Neuro-Ocular Glaucoma Treatment
  • +4
  • NOR ASYIKIN NORDIN,
  • Lidawani Lambuk,
  • Sabarisah Hashim,
  • Syahira Airuddin,
  • Nur-Azida Mohd Nasir,
  • Rohimah Mohamud,
  • Ramlah Kadir
NOR ASYIKIN NORDIN
Universiti Sains Malaysia School of Medical Sciences
Author Profile
Lidawani Lambuk
Universiti Sains Malaysia School of Medical Sciences
Author Profile
Sabarisah Hashim
Universiti Sains Malaysia School of Medical Sciences
Author Profile
Syahira Airuddin
Universiti Sains Malaysia School of Medical Sciences
Author Profile
Nur-Azida Mohd Nasir
Universiti Sains Malaysia School of Medical Sciences
Author Profile
Rohimah Mohamud
Universiti Sains Malaysia School of Medical Sciences
Author Profile
Ramlah Kadir
Universiti Sains Malaysia School of Medical Sciences

Corresponding Author:[email protected]

Author Profile

Abstract

Glaucoma is the most common cause of irreversible vision loss in the world. The only proven method to treat the disease by reduction of intraocular pressure (IOP). IOP act as a modifiable risk factor in glaucoma. Liposomes have been considered as one of the effective pharmaceutical therapies in reducing IOP in glaucoma and receive widespread attention in research due to their special characteristics. Recent studies such as liposomal Latanoprost are still in failure clinical trials. This review focus on the therapeutic application of liposomal in the neuro-ocular brain. The routes of drug administration for the treatment of glaucoma are topical, systemic, periocular and intravitreal. The treatment of glaucoma using drug-carrier liposome shows less invasive and more effective when applied topically since it contains bilayer vesicles which can breach the corneal barrier. To conclude, using the nanocarrier for the topical administration technique is better compared to normal drug application as it is more effective and less invasive.